99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis

CC Quarta, J Zheng, D Hutt, SF Grigore… - European Heart …, 2021 - academic.oup.com
Abstract Aims Technetium-99m-labelled 3, 3-diphosphono-1, 2-propanodicarboxylic acid
(99mTc-DPD scintigraphy) is recognized as highly accurate for the non-invasive diagnosis …

Differentiation of constriction and restriction: complex cardiovascular hemodynamics

JB Geske, NS Anavekar, RA Nishimura, JK Oh… - Journal of the American …, 2016 - jacc.org
Differentiation of constrictive pericarditis (CP) from restrictive cardiomyopathy (RCM) is a
complex and often challenging process. Because CP is a potentially curable cause of heart …

AL amyloidosis for the cardiologist and oncologist: epidemiology, diagnosis, and management

RM Witteles, M Liedtke - Cardio Oncology, 2019 - jacc.org
AL amyloidosis results from clonal production of immunoglobulin light chains, most
commonly arising from a clonal plasma cell disorder. Once considered a nearly uniformly …

18F-Florbetapir Binds Specifically to Myocardial Light Chain and Transthyretin Amyloid Deposits: Autoradiography Study

MA Park, RF Padera, A Belanger, S Dubey… - Circulation …, 2015 - Am Heart Assoc
Background—18F-florbetapir is a promising imaging biomarker for cardiac light chain
amyloidosis (AL) and transthyretin amyloidosis (ATTR). Our aim, using human autopsy …

Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types

J Nativi-Nicolau, MS Maurer - Current Opinion in Cardiology, 2018 - journals.lww.com
Amyloidosis cardiomyopathy: update in the diagnosis and trea... : Current Opinion in Cardiology
Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common …

Efficient 1-hour technetium-99 m pyrophosphate imaging protocol for the diagnosis of transthyretin cardiac amyloidosis

A Masri, S Bukhari, S Ahmad, R Nieves… - Circulation …, 2020 - Am Heart Assoc
Background: Technetium-99 m pyrophosphate protocols for transthyretin cardiac
amyloidosis diagnosis have variably used 1-and 3-hour imaging time points. We …

Cardiac amyloidosis and aortic stenosis: a state-of-the-art review

V Jaiswal, V Agrawal, Y Khulbe, M Hanif… - … Heart Journal Open, 2023 - academic.oup.com
Cardiac amyloidosis is caused by the extracellular deposition of amyloid fibrils in the heart,
involving not only the myocardium but also any cardiovascular structure. Indeed, this …

Multimodality imaging in cardiac amyloidosis: a primer for cardiologists

R Jurcuţ, S Onciul, R Adam, C Stan… - European Heart …, 2020 - academic.oup.com
Amyloidosis is a systemic infiltrative disease, in which unstable proteins misfold, form
aggregates and amyloid fibrils which can deposit in various organs: heart, kidneys, liver …

[HTML][HTML] Advances in the treatment of cardiac amyloidosis

AVS Macedo, PV Schwartzmann… - … treatment options in …, 2020 - Springer
Opinion statement Cardiac amyloidosis is associated with a high mortality rate, a long delay
between the first signs and the diagnosis but a short interval between diagnosis and death …

Coexistence of degenerative aortic stenosis and wild-type transthyretin-related cardiac amyloidosis

S Longhi, M Lorenzini, C Gagliardi, A Milandri… - JACC: Cardiovascular …, 2016 - jacc.org
Degenerative aortic stenosis (AS) is a growing cause of heart failure and death in the
elderly. The majority of patients with symptomatic AS are currently treated with surgical or …